• Register
  • Login

European Journal of Molecular & Clinical Medicine

  • Home
  • Browse
    • Current Issue
    • By Issue
    • By Subject
    • Keyword Index
    • Author Index
    • Indexing Databases XML
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
Advanced Search

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 7, Issue 11
  3. Author

Online ISSN: 2515-8260

Volume7, Issue11

A comparative prospective research looked at the efficacy and tolerability of vitamin C as an add-on treatment to a typical antihypertensive regimen.

    Dr. Krishna Kant Nirala

European Journal of Molecular & Clinical Medicine, 2020, Volume 7, Issue 11, Pages 9048-9053

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

Aim: The aim of the present study to evaluate the efficacy and tolerability of vitamin C as add on therapy to standard antihypertensive regimen.
Methods: A comparative prospective study was conducted in the Department of Pharmacology, Anugrah Narayan Magadh Medical College and Hospital, Gaya, Bihar, India for 1 year. The study was undertaken in mild to moderate hypertensive patients to find out the efficacy and tolerability of vitamin C as an add-on therapy to the standard anti-hypertensive regimen in the reduction of blood pressure and C-reactive protein levels. Total 160 patients with systolic blood pressure in the 140- 179 mm Hg range and diastolic blood pressure in the 90- 109 mm Hg range with C-reactive protein levels in the 10- 12 mg/dl range were recruited for the study out of 720 patients screened.
Results: Out of 720 patients screened, 160 patients were included in this study. They were randomized into four groups, group 1, group 2, group 3 and group 4, each consisting of 40 patients. In group 1, mean age was 44.22±6.88, group II 44.97±9.87, group III 47.01±7.23 whereas in group 4 45.14±6.81. On comparison we found non-significant difference with P value.At baseline there was non-significant difference among all the four group with p value 0.25, whereas at all the visit at 1, 3 and 6 month there was significant difference among the four group with p value <0.01, <0.001 and <0.001. At baseline there was no significant difference among different groups in diastolic BP, whereas there was significant difference among all four groups at all 3 visit i.e 1, 3 and 6 months with p value<0.001.
Conclusion: Vitamin C at the dose of 500 mg OD as an add on therapy to enalapril 5 mg BD causes significant reduction of both systolic and diastolic blood pressure, vitamin C 500 mg OD supplementation to the standard anti-hypertensive drugs may produce better reduction of blood pressure, vitamin C 500 mg may be recommended as an adjuvant to regular anti-hypertensive regimen to reduce cardiovascular and cerebrovascular risks associated with hypertension.
Keywords:
  • PDF (163 K)
  • XML
(2021). A comparative prospective research looked at the efficacy and tolerability of vitamin C as an add-on treatment to a typical antihypertensive regimen.. European Journal of Molecular & Clinical Medicine, 7(11), 9048-9053.
Dr. Krishna Kant Nirala. "A comparative prospective research looked at the efficacy and tolerability of vitamin C as an add-on treatment to a typical antihypertensive regimen.". European Journal of Molecular & Clinical Medicine, 7, 11, 2021, 9048-9053.
(2021). 'A comparative prospective research looked at the efficacy and tolerability of vitamin C as an add-on treatment to a typical antihypertensive regimen.', European Journal of Molecular & Clinical Medicine, 7(11), pp. 9048-9053.
A comparative prospective research looked at the efficacy and tolerability of vitamin C as an add-on treatment to a typical antihypertensive regimen.. European Journal of Molecular & Clinical Medicine, 2021; 7(11): 9048-9053.
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 29
  • PDF Download: 51
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
Journal Information

Publisher:

Email:  editor.ejmcm21@gmail.com

  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap

 

For Special Issue Proposal : editor.ejmcm21@gmail.com

This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus